Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 4/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.51 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.51 |
| ▸ | ITGAL | P20701 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029446 | 0.81 | PDE7A (0.58) | PDE7AICAM1ITGB2ITGALALDH1A1 | |
| SCHEMBL7187676 | 0.76 | ITGB2 (0.80) | PDE7AICAM1ITGB2ITGALPOLB | |
| SCHEMBL4032090 | 0.75 | PDE7A (1.00) | PDE7APOLBALDH1A1NPSR1MAPT | |
| SCHEMBL18319626 | 0.74 | PDE7A (0.53) | PDE7AICAM1ITGB2ITGALALDH1A1 | |
| SCHEMBL5253210 | 0.74 | PDE7A (0.79) | PDE7AICAM1ITGB2ITGALALDH1A1 | |
| Hydrochloric Acid SCHEMBL7615653 | 0.74 | ITGB2 (0.70) | PDE7AICAM1ITGB2ITGALALDH1A1 | |
| SCHEMBL9719813 | 0.74 | SYK (0.52) | PDE7AICAM1ITGB2ITGALALDH1A1 | |
| SCHEMBL8305856 | 0.74 | ALDH1A1 (0.52) | PDE7AICAM1ITGB2ITGALALDH1A1 | |
| SCHEMBL3481634 | 0.73 | PDE7A (0.62) | PDE7APOLBALDH1A1NPSR1MAPT | |
| SCHEMBL4034456 | 0.73 | KMT2A (0.53) | PDE7AICAM1ITGB2ITGALALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767671-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| WO-2005082891-A1 | -QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | PDE7A 3807/4885ICAM1 3706/4885ITGB2 3420/4885 |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | RAF1, KRAS, NRAS | PDE7A 2663/4885ICAM1 4024/4885ITGB2 3691/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | PDE7A 3933/4885ICAM1 3713/4885ITGB2 3163/4885 |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | RAF1, KRAS, NRAS | PDE7A 2663/4885ICAM1 4024/4885ITGB2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.